

AD\_\_\_\_\_

GRANT NUMBER DAMD17-98-1-8057

TITLE: Evaluation of Cyclooxygenase-2 as a Novel Target for Breast Cancer Prevention

PRINCIPAL INVESTIGATOR: Andrew J. Dannenberg, M.D.

CONTRACTING ORGANIZATION: Cornell University Medical College  
New York, New York 10021

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010515 075



FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

AD ✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

NA For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Andrew Dannenberg 7/18/99  
PI - Signature Date

## Table of Contents

	<u>Page Numbers</u>
Front Cover	1
Standard Form 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Key Research Accomplishments	7
Reportable Outcomes	7
Conclusions	7
Appendix	8

## Introduction

Cyclooxygenase (Cox) catalyzes both the synthesis of prostaglandins (PGs) and the intracellular production of mutagens from procarcinogens. The inducible form of cyclooxygenase, Cox-2, is expressed in a wide variety of human cancers and recent evidence suggests that it plays a critical role in tumorigenesis, particularly in colorectal cancer. Both epidemiological and experimental data indicate that nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit Cox activity and PG production, protect against colon cancer. In addition, experiments utilizing Cox-2 knockout mice have shown that loss of Cox-2 leads to a marked reduction in polyp formation in a mouse model of familial adenomatous polyposis coli. These results demonstrate the importance of Cox-2 in intestinal tumorigenesis. However, a role for Cox-2 in breast cancer has not been established. Our research is designed to test whether Cox-2 is important in the pathogenesis of mammary cancer, using Wnt-1 as a model mammary oncogene. Transgenic mice which express Wnt-1 from a mammary specific promoter are predisposed to develop mammary hyperplasia and subsequent carcinomas, and represent a well characterized model of mammary tumorigenesis. Female Wnt-1 transgenic mice with the following Cox-2 genotypes; (+/+), (+/-) and (-/-), are being generated by crossing Cox-2 (+/-) females with Wnt-1 transgenic Cox-2 (+/-) males. As the target mice are generated they will be monitored for development of mammary hyperplasias and adenocarcinomas, to determine whether reduced Cox-2 expression protects against formation of tumors or preneoplastic lesions. Concurrently, the molecular mechanism by which Wnt-1 upregulates Cox-2 is being elucidated in mammary cell culture models. If our research reveals that knocking out the Cox-2 gene protects against mammary tumorigenesis, it will suggest a potential use for selective Cox-2 inhibitors as chemopreventive agents in the treatment of breast cancer.

## Body

Progress during the first year of the grant will be described with specific reference to the individual tasks specified in the Statement of Work.

### **Task 1. Generate breeding stocks of Wnt-1 transgenic and Cox-2 knockout mice for subsequent crosses.**

This is completed. All of these animals have been generated and genotyped by PCR analysis of tail tip DNA. The animals have either been sacrificed or used in subsequent crosses as appropriate. Interestingly, during breeding we observed greater viability of Cox-2 null animals than had previously been observed. Cox-2 null animals either exhibited perinatal mortality or survived for extended periods of time, many still being alive at 8 or 9 months of age. This will have a positive impact on our studies. We had planned to evaluate mammary hyperplasia in Wnt-1 transgenic females of all three Cox-2 genotypes (i.e. wildtype, heterozygote and null), but expected that due to early

mortality of the Cox-2 knockout animals, we would only be able to compare tumor incidence in Cox-2 wildtype and heterozygote animals. However, we now expect that the knockout animals should have sufficient lifespan for us to determine the effect of Cox-2 absence on tumor latency.

**Task 2. Cross Wnt-1 TG males x Cox-2 (+/-) females to generate 10-12 Wnt-1 TG, Cox-2 (+/-) male F1 mice for further breeding, and to generate Wnt-1 TG female mice for analysis of Cox-2 expression in mammary glands.**

This is completed. 10 breeding pairs of Wnt-1 transgenic males and Cox-2 (+/-) females were established, and about 100 offspring genotyped to obtain the required mice for the subsequent cross. All inappropriate genotypes have been sacrificed, and breeding pairs established for task 4.

**Task 3. Analyze Cox-2 expression in mammary tissue from 5 Wnt-1 TG females and 5 wild-type female litter mates.**

Initial analysis by Western blotting has revealed increased expression of Cox-2 in mammary tissue from Wnt-1 transgenic mice compared with wildtype controls. More extensive analyses of Cox-2 expression by Western blotting, Northern blotting and immunohistochemistry will be performed on mice generated during the final cross (Task 4). These mice will have closest strain backgrounds to the cohort of animals retained to analyze tumor incidence, and thus will be most appropriate for this analysis.

**Task 4. Cross Wnt-1 TG, Cox-2 (+/-) males x 18 Cox-2 (+/-) females to generate F2 Wnt-1 TG females with the following Cox-2 genotypes: (+/+), (+/-) and (-/-).**

These crosses are in progress.

**Task 5. Evaluate mammary hyperplasia in 5 animals each of the above F2 genotypes at 8 weeks of age.**

Pending, awaiting generation of sufficient animals with the necessary genotype (Task 4).

**Task 6. Analyze mechanism of Cox-2 regulation by Wnt-1 in cell culture systems.**

Cell lines stably expressing Wnt-1 have been generated by retroviral infection with virus encoding Wnt-1, and assayed for Cox-2 by Northern and Western blotting. We have observed that Wnt-1-expressing cells have elevated Cox-2 protein and RNA, due to transcriptional upregulation of the Cox-2 gene, and consequently produce elevated amounts of  $PGE_2$ . These data have been published and full details can be found in the appended Cancer Research paper (Howe *et al.* (1999) Cancer Research 59, 1572-1577).

Further experiments are currently in progress designed to elucidate the molecular mechanism by which Wnt-1 mediates upregulation of the Cox-2 promoter.

**Tasks 7 & 8.**

Pending, awaiting generation of the necessary animals (Task 4).

## Key Research Accomplishments

Breeding programs were established to generate numerous Wnt-1 transgenic and Cox-2 heterozygote mice for further breeding. Wnt-1 transgenic and Cox-2 heterozygote mice were crossed to generate F1 Wnt-1 transgenic, Cox-2 heterozygote males for final cross. Breeding pairs have been established to generate F2 Wnt-1 transgenic mice of genotypes Cox-2 (+/+), (+/-) and (-/-), to be analyzed for mammary hyperplasia and tumor incidence. We have demonstrated that Wnt-1 expression in mammary epithelial cell lines causes transcriptional upregulation of the Cox-2 gene.

## Reportable Outcomes

1 published paper (Howe et al. (1999) Cancer Research **59**, 1572-1577); appended.

## Conclusions

Much of the progress made to date on this project has involved establishing mice colonies and breeding programs, which constitute necessary preliminary steps to evaluating the effect of Cox-2 gene dosage on Wnt-1-induced mammary hyperplasia and carcinoma formation. However, we have also demonstrated in a cell culture system that Wnt-1 causes transcriptional upregulation of the Cox-2 gene. Consistent with this, we have observed increased Cox-2 protein in mammary glands from Wnt-1 transgenic mice relative to those of control wildtype littermates. These findings are of considerable interest, suggesting that, in addition to its well-established role in colorectal cancer, Cox-2 may also be upregulated during, and contribute to, mammary tumorigenesis. Should our experiments show a reduction in mammary tumorigenesis correlating with reduced Cox-2 gene dosage, a future goal will be to determine whether pharmacological inhibition of Cox-2 protects against mammary cancer.

We are currently using our Wnt-1-expressing cell lines to analyze the molecular mechanism of Cox-2 upregulation by Wnt-1. Cox-2 is upregulated in tumors generated as a consequence of aberrant Wnt-1 expression or mutation of the APC tumor suppressor gene. Since both of these events result in stabilization of  $\beta$ -catenin in the cytosol, and consequently  $\beta$ -catenin/TCF-mediated transcriptional activation, it is tempting to speculate that the Cox-2 gene may be subject to regulation by  $\beta$ -catenin/TCF complexes. However, it is equally possible that other molecular events may contribute to Cox-2 upregulation. Experiments are currently underway to distinguish these possibilities.

# Transcriptional Activation of *Cyclooxygenase-2* in *Wnt-1*-transformed Mouse Mammary Epithelial Cells<sup>1</sup>

Louise R. Howe, Kotha Subbaramaiah, Wen Jing Chung, Andrew J. Dannenberg, and Anthony M. C. Brown<sup>2</sup>

Strang Cancer Research Laboratory, The Rockefeller University, New York, New York 10021 [L. R. H., K. S., W. J. C., A. J. D., A. M. C. B.], and Departments of Cell Biology and Anatomy [L. R. H., A. M. C. B.] and Medicine [K. S., W. J. C., A. J. D.], Weill Medical College of Cornell University, New York, New York 10021

## ABSTRACT

*Wnt-1* acts as a mammary oncogene when ectopically expressed in the mouse mammary gland. *APC* is a tumor suppressor gene, mutations in which cause intestinal tumorigenesis in humans and rodents. Both *Wnt-1* expression and *APC* mutation activate a common signaling pathway involving transcriptional activation mediated by  $\beta$ -catenin/Tcf complexes, but few targets relevant to carcinogenesis have yet been identified. Expression of the inducible prostaglandin synthase cyclooxygenase-2 appears critical for intestinal tumorigenesis resulting from *APC* mutation, suggesting that cyclooxygenase-2 might be a transcriptional target for  $\beta$ -catenin/Tcf complexes. Here, we have investigated the effect of *Wnt-1* on cyclooxygenase-2 expression. *Wnt-1* expression in the mouse mammary epithelial cell lines RAC311 and C57MG induces stabilization of cytosolic  $\beta$ -catenin and morphological transformation. Expression of *Wnt-1* in these cells caused transcriptional up-regulation of the cyclooxygenase-2 gene, resulting in increased levels of cyclooxygenase-2 mRNA and protein. Prostaglandin E<sub>2</sub> production was increased as a consequence of the elevated cyclooxygenase-2 activity and could be decreased by treatment with a selective cyclooxygenase-2 inhibitor. Cyclooxygenase-2 thus appears to be a common downstream target for *APC* mutation and *Wnt-1* expression. In view of the critical role of cyclooxygenase-2 in intestinal tumorigenesis, cyclooxygenase-2 up-regulation in response to *Wnt* signaling may contribute to *Wnt*-induced mammary carcinogenesis.

## INTRODUCTION

*Wnt-1* was originally identified as a mammary oncogene activated by proviral insertions of mouse mammary tumor virus (1-3). Ectopic expression of *Wnt-1* under the control of a mouse mammary tumor virus promoter leads to extensive mammary hyperplasia and subsequent generation of adenocarcinomas in mice (4). Cell culture experiments demonstrate that multiple *Wnt* gene family members including *Wnt-1* can cause partial cellular transformation of some epithelial and fibroblastic cell lines (5-12). Collectively, these data implicate *Wnt-1* as an oncogene when inappropriately expressed. Several *WNT* gene family members have been found to be overexpressed in a proportion of human breast cancers and may therefore contribute to carcinogenesis in humans (13-17).

The *Wnt-1* gene encodes a secreted protein that functions as an extracellular ligand capable of promoting mitogenesis (18-21). *Wnt-1* appears to signal via a unique pathway, thought to be initiated by interaction of *Wnt-1* with a member of the Frizzled family of seven-transmembrane receptors, leading to stabilization of a cytosolic pool of  $\beta$ -catenin (22). Accumulated  $\beta$ -catenin can translocate to the nucleus, interact with Tcf transcription factors, and thereby mediate transcriptional activation (11, 23-31).

$\beta$ -Catenin/Tcf-mediated transcriptional activation has recently been implicated in human carcinogenesis. Elevated cytosolic  $\beta$ -catenin and transcriptionally active  $\beta$ -catenin/Tcf complexes have been detected in both colon carcinomas and melanomas (32-34).  $\beta$ -Catenin accumulation can occur as a consequence of mutation of either the  $\beta$ -catenin gene itself or the tumor suppressor gene *APC*, because wild-type *APC* protein contributes to  $\beta$ -catenin destabilization (32-36). Mutations in *APC* cause intestinal tumorigenesis in humans and mice. Although the molecular mechanism by which *APC* mutation induces tumorigenesis is unclear, many data implicate cyclooxygenase enzymes in this process (37). Cox-1<sup>3</sup> and Cox-2 are constitutively expressed and inducible isoforms of prostaglandin synthase, respectively (gene symbols, *Ptgs1* and *Ptgs2*; Ref. 38). *COX-2* expression has been detected in intestinal tumors of both mice and humans with *APC* mutations (39-41). Genetic ablation of the *Cox-2* gene or pharmacological inhibition of Cox-2 activity dramatically reduces the incidence of intestinal tumors in *Apc* mutant mice (42).

Thus, both *APC* mutation and ectopic *Wnt-1* expression can cause tumorigenesis, and this may be, at least in part, via a common signaling pathway involving  $\beta$ -catenin/Tcf complexes. Furthermore, Cox-2 appears critical for tumor formation resulting from *APC* mutation. Consequently, we reasoned that Cox-2 might also be a target for *Wnt-1* signaling and might potentially contribute to *Wnt-1*-induced mammary tumorigenesis. We therefore tested the effect of *Wnt-1* expression on Cox-2 in mouse mammary epithelial cells. Here we show that *Wnt-1* expression in RAC311 and C57MG cells causes increased transcription of *Cox-2*, resulting in elevated Cox-2 protein levels. An increase in PGE<sub>2</sub> synthesis is also observed in *Wnt-1*-expressing cells, which can be reversed by treatment with a selective Cox-2 inhibitor. These data may be significant not only in terms of *Wnt*-mediated carcinogenesis in the mouse but also in relation to human cancers in which components of the *Wnt* signaling pathway are activated.

## MATERIALS AND METHODS

**Cell Culture.** Two mouse mammary epithelial cell lines were used, C57MG (43) and RAC311, a clonal subline derived from RAC311c (44, 45). RAC311 cells were grown in DMEM (4.5 g/l D-glucose) containing 10% fetal bovine serum (Life Technologies, Inc.), 100 units/ml penicillin, and 100  $\mu$ g/ml streptomycin. C57MG growth medium was supplemented with 10  $\mu$ g/ml insulin (Sigma). Cells were infected with MV7 or MVWnt-1 retrovirus using helper-free virus stocks as described previously (21). Approximately 50-100 G418-resistant colonies were pooled to generate the pooled populations designated RAC/MV7, RAC/Wnt-1, C57/MV7, and C57/Wnt-1. A clonal subline of RAC/Wnt-1 was derived by limiting dilution, selected on the basis of highly transformed morphology, and designated RAC/Wnt-1 #9. For cell lysate and RNA preparation, cells were plated at  $1 \times 10^6$  cells per 10-cm dish and grown until MV7-infected control cells were confluent (5 days for RAC/MV7; 4 days for C57/MV7). DFU was a generous gift of the Merck Frosst Center for Therapeutic Research (Quebec, Canada).

**Cell Lysate Preparation and Analysis.** For *Wnt-1* protein analysis, ECM fractions were prepared after removing the cells from the dishes by incubation

Received 10/22/98; accepted 1/27/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This study was funded by NIH Grants CA47207 (to A. M. C. B.) and CA68136 (to A. J. D.), by Department of the Army Grant BC972610, and by donations to the Strang Cancer Prevention Center from the Fashion Footwear Association of New York. L. R. H. is a Lilith fellow, funded in part by proceeds from the Lilith Fair.

<sup>2</sup> To whom requests for reprints should be addressed, at Strang Cancer Research Laboratory, The Rockefeller University, Box 231, 1230 York Avenue, New York, NY 10021. Phone: (212) 734-0567, extension 232; Fax: (212) 472-9471; E-mail: amcbrown@mail.med.cornell.edu.

<sup>3</sup> The abbreviations used are: Cox, cyclooxygenase; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone; ECM, extracellular matrix; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

with Dulbecco's PBS (Life Technologies, Inc.) containing 2 mM EDTA. ECM remaining on the plates was solubilized in boiling Laemmli SDS sample buffer and stored at  $-20^{\circ}\text{C}$ . For analysis of cytosolic  $\beta$ -catenin levels, lysates were prepared as described (46), and total protein was assayed using Bio-Rad Protein Assay reagent. For Cox-2 protein analysis, lysates were prepared essentially as described (47). Cells were washed twice with PBS and harvested in lysis buffer containing 150 mM NaCl, 100 mM Tris-Cl (pH 8.0), 1% Tween 20, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 50 mM diethylthiocarbamic acid. After one cycle of freeze-thawing at  $-20^{\circ}\text{C}$ , cells were sonicated (three times for 15 s each time) on ice, then debris was pelleted by centrifugation at  $10,000 \times g$  for 10 min at  $4^{\circ}\text{C}$ . Supernatants were stored at  $-80^{\circ}\text{C}$ , and proteins were assayed using a Lowry-based protein assay kit (Sigma).

For Western analysis, samples were subjected to SDS-PAGE as follows: Wnt-1 ECM fractions, 10% gel;  $\beta$ -catenin samples, 8% gel, 5  $\mu\text{g}$  of protein; Cox-2 lysates, 10% gel, 50  $\mu\text{g}$  of protein. Proteins were transferred to polyvinylidene fluoride membrane (Immobilon; Millipore), blotted with anti-Wnt-1 antibody (MC123; Ref. 21), anti- $\beta$ -catenin antibody (Transduction Laboratories; Ref. 46), or anti-Cox-2 antibody (715; Ref. 47), and developed with Amersham enhanced chemiluminescence reagents. The anti-Cox-2 antibody 715 was a rabbit polyclonal antibody, raised against the unique 18-amino acid sequence from the COOH-terminal region of human Cox-2, which does not react with Cox-1.

**RNA Preparation and Northern Blotting.** RNA was prepared from confluent cells using RNAzol B (Tel-Test, Inc.) according to the manufacturer's instructions. Twenty  $\mu\text{g}$  of RNA were subjected to electrophoresis in 1% agarose/formaldehyde/3-[*N*-morpholino]propanesulfonic acid gels and transferred to Zeta-Probe membrane (Bio-Rad). Radiolabeled random-primed probes were prepared using the Rediprime DNA labeling system (Amersham), and hybridization was undertaken at  $65^{\circ}\text{C}$  in 0.5 M  $\text{Na}_2\text{HPO}_4$  (pH 7.2), 7% SDS, and 1 mM EDTA (48). Washes were performed in 40 mM  $\text{Na}_2\text{HPO}_4$  (pH 7.2), 1% SDS at  $65^{\circ}\text{C}$ . Probes used were murine *Cox-2* (TIS-10; a gift from H. R. Herschman, University of California at Los Angeles, Los Angeles, CA), murine *Cox-1* (a gift from W. L. Smith, Michigan State University, East Lansing, MI), and murine GAPDH (obtained from A. Ashworth, Institute of Cancer Research, London, England). GAPDH was used to demonstrate equal loading of each lane.

**Nuclear Run-Ons.** Nuclei were prepared, and nuclear run-ons were performed as described (47).

Autoradiographic exposures of both Northern blots and nuclear run-ons were quantitated by analysis on a Macintosh computer using the public domain NIH Image program (developed at the United States NIH and available on the Internet at <http://rsb.info.nih.gov/nih-image/>). Values obtained were normalized to those obtained for GAPDH and 18S rRNA for Northern blots and nuclear run-ons, respectively.

**PGE<sub>2</sub> Assays.** Cells were plated in 12-well plates at  $4 \times 10^4$  cells/well and grown to confluence. Culture medium was collected and assayed for PGE<sub>2</sub> by enzyme immunoassay (Cayman Co., Ann Arbor, MI). To assay PGE<sub>2</sub> production in the presence of excess arachidonic acid (AA "spiked"), cells were incubated with fresh medium containing 10  $\mu\text{M}$  arachidonic acid for 30 min, and then this medium was harvested and assayed as above. For experiments assaying the effect of DFU on PGE<sub>2</sub> production, cells were plated in 6-cm dishes at  $3 \times 10^5$  cells/dish. DFU was added in fresh medium 72 h after plating and readed at 96 h. PGE<sub>2</sub> production was assayed at 120 h after plating, at which time control cells were confluent.

## RESULTS AND DISCUSSION

To examine the effect of Wnt-1 on *Cox-2* expression, we generated fresh cell populations expressing *Wnt-1* by infection of the mouse mammary epithelial cell lines C57MG and RAC311 with retrovirus encoding Wnt-1 (MVWnt-1) or control retrovirus (MV7). As observed previously (5, 6), both C57/Wnt-1 and RAC/Wnt-1 cells appeared morphologically transformed and grew to higher cell densities than control cells (C57/MV7 and RAC/MV7, respectively). An additional clonal subline, RAC/Wnt-1 #9, was generated from RAC/Wnt-1 by limiting dilution and selected because of its high degree of morphological transformation. Western blot analysis using an anti-

Wnt-1 antibody revealed that RAC/Wnt-1 #9 produced more Wnt-1 protein than the pooled RAC/Wnt-1 population (Fig. 1A). Therefore, we included both RAC/Wnt-1 and RAC/Wnt-1 #9 in subsequent analyses. As demonstrated previously, expression of *Wnt-1* in C57MG led to accumulation of uncomplexed cytosolic  $\beta$ -catenin (Refs. 46 and 49; data not shown). In addition, cytosolic  $\beta$ -catenin was elevated in RAC311 cells expressing *Wnt-1* (Fig. 1B), and higher levels were detected in RAC/Wnt-1 #9 relative to RAC/Wnt-1, correlating with relative Wnt-1 protein production.

Cox-2 protein levels in control and *Wnt-1*-expressing cell lines were analyzed by Western blotting (Fig. 2). C57/MV7 exhibited a markedly higher basal amount of Cox-2 than RAC/MV7, in which Cox-2 protein was virtually undetectable. In both C57MG and RAC311 cell lines, however, expression of *Wnt-1* led to an increase in Cox-2 protein, and Cox-2 protein was more abundant in RAC/Wnt-1 #9 than in RAC/Wnt-1, correlating with *Wnt-1* expression levels. Analysis of Cox-2 RNA by Northern blotting demonstrated that




Fig. 1. Characterization of RAC311 cells expressing *Wnt-1*. RAC/MV7, RAC/Wnt-1, and RAC/Wnt-1 #9 cells were generated by retroviral infection as described in "Materials and Methods." Cells were analyzed by Western blotting for Wnt-1 protein and cytosolic  $\beta$ -catenin levels. A, *Wnt-1* expression. ECM fractions were prepared and assayed for Wnt-1 protein as described in "Materials and Methods." Anti-Wnt-1 antibody MC123 detected two bands of  $M_r$  42,000 and  $M_r$  44,000 in *Wnt-1*-expressing cells, as observed previously (71). These represent differentially glycosylated forms of Wnt-1 protein (20). No Wnt-1 protein was detected in ECM from control RAC/MV7 cells. B, cytosolic  $\beta$ -catenin. Cytosol fractions were prepared from cells and assayed for  $\beta$ -catenin as described in "Materials and Methods." The position of a  $M_r$  97,000 molecular weight marker is shown.




Fig. 2. Cox-2 protein is increased by *Wnt-1* expression. Lysates were prepared from C57MG-derived cells (A) and RAC311-derived cells (B). Fifty  $\mu$ g of lysate were analyzed by Western blotting for Cox-2 as described in "Materials and Methods," using rabbit polyclonal anti-Cox-2 antibody 715. Data shown in A and B are from separate experiments. The position of a *M*, 69,000 molecular weight marker is shown.




Fig. 3. Cox-2 mRNA is increased in cells expressing *Wnt-1*. Total RNA was prepared from cells, and 20  $\mu$ g of each RNA sample were analyzed by Northern blotting as described in "Materials and Methods." The blot was probed sequentially with a murine *Cox-2* probe and a murine GAPDH probe. Cox-2 signals were quantitated using the program NIH Image and normalized to those obtained from GAPDH probing. Values obtained are expressed relative to the control MV7-infected cell line in each case. C57/MV7, 100%; C57/Wnt-1, 500%; RAC/MV7, 100%; RAC/Wnt-1, 174%; RAC/Wnt-1 #9, 327%.

Cox-2 mRNA levels closely reflected the changes observed in Cox-2 protein (Fig. 3), suggesting the effect of *Wnt-1* on Cox-2 was likely to be due to transcriptional activation of the *Cox-2* gene. To test this directly, nuclear run-on assays were performed. These and subsequent assays were performed in the RAC311-derived cell lines in preference to C57MG-derived lines, because the latter tend to lose *Wnt-1* expression during continuous culture.<sup>4</sup> The rates of transcription from the *Cox-2* gene in RAC/Wnt-1 and RAC/Wnt-1 #9 were increased to 270 and 400%, respectively, relative to that in RAC/MV7 (Fig. 4), mirroring the differences observed in Cox-2 RNA and protein. Thus, expression of *Wnt-1* in RAC311, and most likely C57MG, causes transcriptional activation of the *Cox-2* gene.

Cox-2 is an inducible isoform of prostaglandin synthase (38). Thus, one predicted functional consequence of *Cox-2* up-regulation would be an increase in prostaglandin synthesis, of which PGE<sub>2</sub> is the predominant eicosanoid produced by most epithelial cells. We therefore assayed PGE<sub>2</sub> production in RAC311-derived cell lines. Spontaneous production of PGE<sub>2</sub> in RAC/Wnt-1 and RAC/Wnt-1 #9 was increased by 240 and 420%, respectively, over that in RAC/MV7 (Fig.

5, "spontaneous"). Spontaneous PGE<sub>2</sub> production was also measured in C57MG-derived lines and was increased ~100% in C57/Wnt-1 cells relative to C57/MV7 (data not shown). Given that arachidonic acid is the substrate from which cyclooxygenases synthesize prostaglandins, incubation of cells with excess arachidonic acid can increase PGE<sub>2</sub> production. In our experiments, treatment of the cells with arachidonic acid increased the absolute amounts of PGE<sub>2</sub> synthesis (Fig. 5, "AA spiked"), but PGE<sub>2</sub> production was still elevated in *Wnt-1*-expressing cells relative to RAC/MV7. This suggests that the measured spontaneous synthesis rates reflected relative levels of Cox-2 activity in the cells, rather than differential availability of arachidonic acid.

The observed increases in PGE<sub>2</sub> synthesis in *Wnt-1*-expressing cells could also be a consequence of changes in the level of Cox-1. Although *Cox-1* is constitutively and ubiquitously expressed, there have been reports of ligand-induced *Cox-1* up-regulation (50–53). Therefore, we addressed the involvement of Cox-1 using two assays: (a) we measured Cox-1 mRNA by Northern blotting and found little or no increase in Cox-1 mRNA in RAC/Wnt-1 and C57MG/Wnt-1, respectively, relative to control cells (Fig. 6); and (b) we tested the relative contribution of Cox-1 and Cox-2 to PGE<sub>2</sub> production in the RAC311-derived cell lines by using DFU, a selective Cox-2 inhibitor. DFU has at least a 1000-fold specificity for Cox-2 relative to Cox-1 in tissue culture cells (54). RAC/MV7, RAC/Wnt-1, and RAC/Wnt-1 #9 were treated with varying concentrations of DFU for 48 h, and culture supernatants were then assayed for PGE<sub>2</sub>. A dose-dependent inhibition of PGE<sub>2</sub> production was observed, with 1  $\mu$ M DFU being sufficient to reduce PGE<sub>2</sub> production to approximately the same basal level in all three cell lines (Fig. 7). Higher concentrations of DFU did not cause any additional inhibition of PGE<sub>2</sub> synthesis. The residual PGE<sub>2</sub> production observed in all cell lines after inhibition of Cox-2 with DFU is presumed to reflect Cox-1 activity. Because the amount of Cox-1-mediated PGE<sub>2</sub> synthesis is apparently constant in all three cell lines, we conclude that the enhanced production of PGE<sub>2</sub> in *Wnt-1*-transformed cells is attributable to increased Cox-2 activity, consistent with the observed differences in Cox-2 RNA and protein levels. Cell morphology was unaffected by treatment with DFU (data not shown). The failure of DFU to affect morphological transformation of *Wnt-1*-expressing cells suggests that elevated prostanoid pro-




Fig. 4. *Cox-2* transcription is up-regulated in RAC311 cells expressing *Wnt-1*. Nuclei were prepared, and nuclear run-on assays were performed as described in "Materials and Methods." Labeled nascent transcripts were hybridized to 18S rRNA and *Cox-2* cDNAs, which were immobilized on nitrocellulose. Signals were quantitated using the program NIH Image, and Cox-2 was normalized to 18S rRNA. Values obtained are expressed relative to RAC/MV7. RAC/MV7, 100%; RAC/Wnt-1, 267%; RAC/Wnt-1 #9, 399%.

<sup>4</sup> A. M. C. Brown, unpublished observations.




Fig. 5. PGE<sub>2</sub> production is increased by expression of *Wnt-1*. Cells were grown for 5 days after plating to achieve confluence, during which time no medium change was performed. Growth medium from the cells was harvested and assayed using enzyme immunoassay to measure spontaneous PGE<sub>2</sub> production (SPONTANEOUS, light hatching). Cells were incubated for an additional 30 min in fresh medium containing 10 μM sodium arachidonate. The medium was then collected and assayed for PGE<sub>2</sub> (AA SPIKED, dark hatching). Results were normalized to μg of protein obtained from the cells after harvesting of medium. Results shown are mean values of six replicates; bars, SD. PGE<sub>2</sub> production from both *Wnt-1*-expressing cell lines was significantly greater than that from RAC/MV7 control cells (\*,  $P < 0.001$ ; +,  $P < 0.003$ ).

duction by *Cox-2* is not necessary for maintenance of the transformed phenotype of these cells *in vitro*.

We have shown here that expression of *Wnt-1* in two mammary epithelial cell lines causes elevated expression and activity of *Cox-2*, via transcriptional activation, resulting in increased PGE<sub>2</sub> synthesis. The *Cox-2* gene was initially identified as an early response gene up-regulated in response to phorbol ester and serum and was subsequently found to be induced by multiple agents, particularly during inflammatory responses (38). A large body of evidence has accumulated implicating *Cox-2* in intestinal carcinogenesis. *COX-2* expression is frequently detected in tumor tissue (39, 40, 55–58), and the incidence of intestinal tumorigenesis in both mice and humans can be reduced by pharmacological agents that inhibit *Cox* activity (41, 42, 59–64). A crucial role for *Cox-2* in tumorigenesis has been demonstrated by Oshima *et al.* (1996; Ref. 42), who found that intestinal polyposis in *Apc* mutant mice was markedly reduced by genetic ablation of *Cox-2*. However, *Cox-2* induction in response to Wnt proteins has not been demonstrated previously.

The mechanism by which *Wnt-1* activates *Cox-2* transcription is unclear. Given that *COX-2* induction occurs in response to *Wnt-1* expression and *APC* mutation, both of which result in cytosolic β-catenin accumulation, our initial expectation was that the *Cox-2* promoter might be subject to direct regulation by β-catenin/Tcf complexes. The human *COX-2* promoter contains two potential Tcf-binding sites, although their overlap with the canonical TCF binding

motif is only partial (ACTTTGATC and TCTTTGTAG compared with CCTTTGA/TA/TC; Ref. 27). One of these sites is not conserved in the murine *Cox-2* promoter, and the other lies outside the sequence presently reported for the mouse promoter. To investigate the mechanism of regulation, we have performed transient transfection assays using a human *COX-2* promoter-luciferase reporter construct but thus far have been unable to detect increased reporter activity as a result of β-catenin overexpression. Thus, it is possible that *Cox-2* transcription may not be directly regulated by β-catenin/Tcf complexes but may be activated in *Wnt-1*-expressing cells by alternative transcription factors. We also cannot exclude the possibility that *Cox-2* induction is a more downstream or indirect consequence of Wnt signaling.




Fig. 6. Effect of *Wnt-1* expression on *Cox-1* mRNA. RNA was prepared, and a Northern blot was generated as described in "Materials and Methods" using 20 μg of each RNA. The blot was probed sequentially with a murine *Cox-1* probe and a murine GAPDH probe. *Cox-1* signals were quantitated using the program NIH Image and normalized to those obtained from GAPDH probing. Values obtained are expressed relative to the control MV7-infected cell line in each case. C57/MV7, 100%; C57/Wnt-1, 70%; RAC/MV7, 100%; RAC/Wnt-1, 118%; RAC/Wnt-1 #9, 163%.




Fig. 7. Inhibition of PGE<sub>2</sub> production by a selective *Cox-2* inhibitor DFU. Cells were treated with the indicated concentrations of DFU for 48 h. Culture medium was harvested and assayed for PGE<sub>2</sub> by enzyme immunoassay to determine spontaneous release of PGE<sub>2</sub>. Results were normalized to μg of protein obtained from the cells after harvesting of the medium. Mean values of two replicates are shown; bars, spread.

Because *Wnt-1* is a mammary oncogene, our data suggest that *Cox-2* up-regulation might also contribute to mammary tumorigenesis. Consistent with this idea, *Cox-2* is expressed in ras- and virally transformed mammary cells, as well as in some human breast cancers and breast cancer cell lines (47, 65, 66). Interestingly, despite abundant evidence of the importance of *Cox-2* during intestinal tumorigenesis, the precise mechanism by which *Cox-2* contributes is unclear. Prostaglandin overproduction is likely to have multiple consequences. Prostaglandins can exert local immunosuppressive effects that could facilitate tumorigenesis (37, 67). Additionally changes in gene expression can occur because selected prostaglandins are ligands of the peroxisome proliferator-activated receptor  $\gamma$  (68). *Cox-2* induction in tumors may promote survival of cells otherwise destined to undergo apoptotic cell death; negative regulation of apoptosis by *Cox-2* overexpression has been demonstrated in intestinal epithelial cells (69). Recent data also demonstrate a role for *Cox-2* in angiogenesis. Selective inhibition of *Cox-2* reduces secretion of angiogenic factors from colon cancer cells, thereby suppressing *de novo* formation of endothelial tubules *in vitro* (70). Because of the pleiotropic consequences of *Cox-2* overexpression, it is difficult to predict what role *Cox-2* might play in *Wnt-1*-induced mammary tumorigenesis. Transgenic mice that express *Wnt-1* ectopically in the mammary gland display extensive mammary hyperplasia at an early age and subsequently develop mammary adenocarcinomas stochastically after a latent period of several months (4). If *Cox-2* contributes to *Wnt-1*-mediated tumorigenesis *in vivo*, it could do so either at the initial hyperplastic stage or by affecting progression to carcinoma. Our findings may also be pertinent to human breast cancer. Although expression of *WNT-1* itself in human mammary tissue has not been reported, several other members of the *WNT* gene family are overexpressed in human breast tumors relative to normal tissue (13–16). A number of *Wnt* proteins exhibit functional redundancy with *Wnt-1*, inducing stabilization of cytosolic  $\beta$ -catenin and morphological transformation of mammary cells (8, 10). Therefore, it is likely that some of the *WNT* genes overexpressed in human breast cancers may have transcriptional consequences similar to those of *Wnt-1*.

## ACKNOWLEDGMENTS

We thank A. Ashworth, H. R. Herschman, and W. L. Smith for plasmids. The generous assistance of J. R. Timmer with production of figures is gratefully acknowledged.

## REFERENCES

- Nusse, R., and Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. *Cell*, **31**: 99–109, 1982.
- Peters, G., Brookes, S., Smith, R., and Dickson, C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. *Cell*, **33**: 369–377, 1983.
- Nusse, R., van Ooyen, A., Cox, D., Fung, Y. K. T., and Varmus, H. Mode of proviral activation of a putative mammary oncogene (*int-1*) on mouse chromosome 15. *Nature (Lond.)*, **307**: 131–136, 1984.
- Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., Parslow, T., and Varmus, H. E. Expression of the *int-1* gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. *Cell*, **55**: 619–625, 1988.
- Brown, A. M. C., Wildin, R. S., Prendergast, T. J., and Varmus, H. E. A retrovirus vector expressing the putative mammary oncogene *int-1* causes partial transformation of a mammary epithelial cell line. *Cell*, **46**: 1001–1009, 1986.
- Rijsewijk, F., van Deemter, L., Wagenaar, E., Sonnenberg, A., and Nusse, R. Transfection of the *int-1* mammary oncogene in cuboidal RAC mammary cell line results in morphological transformation and tumorigenicity. *EMBO J.*, **6**: 127–131, 1987.
- Bradbury, J. M., Niemeyer, C. C., Dale, T. C., and Edwards, P. A. W. Alterations of the growth characteristics of the fibroblast cell line C3H 10T1/2 by members of the *Wnt* gene family. *Oncogene*, **9**: 2597–2603, 1994.
- Wong, G. T., Gavin, B. J., and McMahon, A. P. Differential transformation of mammary epithelial cells by *Wnt* genes. *Mol. Cell. Biol.*, **14**: 6278–6286, 1994.
- Christiansen, J. H., Monkley, S. J., and Wainwright, B. J. Murine WNT11 is a secreted glycoprotein that morphologically transforms mammary epithelial cells. *Oncogene*, **12**: 2705–2711, 1996.
- Shimizu, H., Julius, M. A., Giarré, M., Zheng, Z., Brown, A. M. C., and Kitajewski, J. Transformation by *Wnt* family proteins correlates with regulation of  $\beta$ -catenin. *Cell Growth Differ.*, **8**: 1349–1358, 1997.
- Young, C. S., Kitamura, M., Hardy, S., and Kitajewski, J. *Wnt-1* induces growth, cytosolic  $\beta$ -catenin, and *Tcf/Lef* transcriptional activation in Rat-1 fibroblasts. *Mol. Cell. Biol.*, **18**: 2474–2485, 1998.
- Bafico, A., Gazit, A., Wu-Morgan, S. S., Yaniv, A., and Aaronson, S. A. Characterization of *Wnt-1* and *Wnt-2* induced growth alterations and signaling pathways in NIH3T3 fibroblasts. *Oncogene*, **16**: 2819–2825, 1998.
- Huguot, E. L., McMahon, J. A., McMahon, A. P., Bicknell, R., and Harris, A. L. Differential expression of human *Wnt* genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. *Cancer Res.*, **54**: 2615–2621, 1994.
- Iozzo, R. V., Eichstetter, I., and Danielson, K. G. Aberrant expression of the growth factor *Wnt-5A* in human malignancy. *Cancer Res.*, **55**: 3495–3499, 1995.
- Dale, T. C., Weber-Hall, S. J., Smith, K., Huguot, E. L., Jayatilake, H., Gusterson, B. A., Shuttleworth, G., O'Hare, M., and Harris, A. L. Compartment switching of *WNT-2* expression in human breast tumors. *Cancer Res.*, **56**: 4320–4323, 1996.
- Bui, T. D., Rankin, J., Smith, K., Huguot, E. L., Ruben, S., Strachan, T., Harris, A. L., and Lindsay, S. A novel human *Wnt* gene, *WNT10B*, maps to 12q13 and is expressed in human breast carcinomas. *Oncogene*, **14**: 1249–1253, 1997.
- Bergstein, I., and Brown, A. M. C. *WNT* genes and breast cancer. In: A. M. Bowcock (ed.), *Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics*, pp. 181–198. Totowa, NJ: Humana Press, 1999.
- van Ooyen, A., and Nusse, R. Structure and nucleotide sequence of the putative mammary oncogene *int-1*; proviral insertions leave the protein-encoding domain intact. *Cell*, **39**: 233–240, 1984.
- Brown, A. M. C., Papkoff, J., Fung, Y. K., Shackelford, G. M., and Varmus, H. E. Identification of protein products encoded by the proto-oncogene *int-1*. *Mol. Cell. Biol.*, **7**: 3971–3977, 1987.
- Papkoff, J., Brown, A. M. C., and Varmus, H. E. The *int-1* proto-oncogene products are glycoproteins that appear to enter the secretory pathway. *Mol. Cell. Biol.*, **7**: 3978–3984, 1987.
- Bradley, R. S., and Brown, A. M. C. A soluble form of *Wnt-1* protein with mitogenic activity on mammary epithelial cells. *Mol. Cell. Biol.*, **15**: 4616–4622, 1995.
- Cadigan, K. M., and Nusse, R. *Wnt* signaling: a common theme in animal development. *Genes Dev.*, **11**: 3286–3305, 1997.
- Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., and Clevers, H. *XTcf-3* transcription factor mediates  $\beta$ -catenin-induced axis formation in *Xenopus* embryos. *Cell*, **86**: 391–399, 1996.
- Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. Functional interaction of  $\beta$ -catenin with the transcription factor LEF-1. *Nature (Lond.)*, **382**: 638–642, 1996.
- Huber, O., Korn, R., McLaughlin, J., Ohsugi, M., Herrmann, B. G., and Kemler, R. Nuclear localization of  $\beta$ -catenin by interaction with transcription factor LEF-1. *Mech. Dev.*, **59**: 3–10, 1996.
- Brunner, E., Peter, O., Schweizer, L., and Basler, K. *pangolin* encodes a *Lef-1* homologue that acts downstream of Armadillo to transduce the *Wingless* signal in *Drosophila*. *Nature (Lond.)*, **385**: 829–833, 1997.
- van de Wetering, M., Cavallo, R., Dooijes, D., van Beest, M., van Es, J., Loureiro, J., Ypma, A., Hursh, D., Jones, T., Bejsovec, A., Peifer, M., Morin, M., and Clevers, H. Armadillo coactivates transcription driven by the product of the *Drosophila* segment polarity gene *dTCF*. *Cell*, **88**: 789–799, 1997.
- Riese, J., Yu, X., Munsterlyn, A., Eresh, S., Hsu, S.-C., Grosschedl, R., and Bienz, M. LEF-1, a nuclear factor coordinating signaling inputs from *wingless* and *decapentaplegic*. *Cell*, **88**: 777–787, 1997.
- Porfiri, E., Rubinfield, B., Albert, I., Hovanec, K., Waterman, M., and Polakis, P. Induction of a  $\beta$ -catenin-LEF-1 complex by *wnt-1* and transforming mutants of  $\beta$ -catenin. *Oncogene*, **15**: 2833–2839, 1997.
- Fagotto, F., Gluck, U., and Gumbiner, B. M. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of  $\beta$ -catenin. *Curr. Biol.*, **8**: 181–190, 1998.
- Korinek, V., Barker, N., Willert, K., Molenaar, M., Roose, J., Wagenaar, G., Markman, M., Lamers, W., Destree, O., and Clevers, H. Two members of the *Tcf* family implicated in *Wnt*/ $\beta$ -catenin signaling during embryogenesis in the mouse. *Mol. Cell. Biol.*, **18**: 1248–1256, 1998.
- Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., and Clevers, H. Constitutive transcriptional activation by a  $\beta$ -catenin-*Tcf* complex in APC<sup>-/-</sup> colon carcinoma. *Science (Washington DC)*, **275**: 1784–1787, 1997.
- Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. Activation of  $\beta$ -catenin-*Tcf* signaling in colon cancer by mutations in  $\beta$ -catenin or APC. *Science (Washington DC)*, **275**: 1787–1790, 1997.
- Rubinfield, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. Stabilization of  $\beta$ -catenin by genetic defects in melanoma cell lines. *Science (Washington DC)*, **275**: 1790–1792, 1997.
- Munemitsu, S., Albert, I., Souza, B., Rubinfield, B., and Polakis, P. Regulation of intracellular  $\beta$ -catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc. Natl. Acad. Sci. USA*, **92**: 3046–3050, 1995.
- Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Mutational analysis of the APC/ $\beta$ -catenin/*Tcf* pathway in colorectal cancer. *Cancer Res.*, **58**: 1130–1134, 1998.

37. Subbaramaiah, K., Zakim, D., Weksler, B. B., and Dannenberg, A. J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. *Proc. Soc. Exp. Biol. Med.*, *216*: 201-210, 1997.
38. Herschman, H. R. Prostaglandin synthase 2. *Biochim. Biophys. Acta*, *1299*: 125-140, 1996.
39. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. *Cancer Res.*, *55*: 2556-2559, 1995.
40. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lampe, L. W., Nanney, L. B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. *Gastroenterology*, *111*: 1134-1140, 1996.
41. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Abreu-Goriss, M., Newmark, H. L., Lipkin, M. L., DeCossé, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. *Cancer Res.*, *56*: 2556-2560, 1996.
42. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in *Apc<sup>Δ716</sup>* knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell*, *87*: 803-809, 1996.
43. Vaidya, A. B., Lasfargues, E. Y., Sheffield, J. B., and Coutinho, W. G. Murine mammary tumor virus (MMuTV) infection of an epithelial cell line established from C57BL/6 mouse mammary glands. *Virology*, *90*: 12-22, 1978.
44. Ramakrishna, N. R., and Brown, A. M. C. *Wingless*, the *Drosophila* homolog of the proto-oncogene *Wnt-1*, can transform mouse mammary epithelial cells. *Dev.* *119*, Suppl.: 95-103, 1993.
45. Sonnenberg, A., van Balen, P., Hilgers, J., Schuurin, E., and Nusse, R. Oncogene expression during progression of mouse mammary tumor cells: activity of a proviral enhancer and the resulting expression of *int-2* is influenced by the state of differentiation. *EMBO J.*, *6*: 121-125, 1987.
46. Giarre, M., Semenov, M. V., and Brown, A. M. C. WNT signaling stabilizes the dual function protein  $\beta$ -catenin in diverse cell types. *Ann. NY Acad. Sci.*, *857*: 43-55, 1998.
47. Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., and Dannenberg, A. J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. *Cancer Res.*, *56*: 4424-4429, 1996.
48. Church, G. M., and Gilbert, W. Genomic sequencing. *Proc. Natl. Acad. Sci. USA*, *81*: 1991-1995, 1984.
49. Papkoff, J., Rubinfeld, B., Schryver, B., and Polakis, P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. *Mol. Cell. Biol.*, *16*: 2128-2134, 1996.
50. Oshima, T., Yoshimoto, T., Yamamoto, S., Kumegawa, M., Yokoyama, C., and Tanabe, T. cAMP-dependent induction of fatty acid cyclooxygenase mRNA in mouse osteoblastic cells (MC3T3-E1). *J. Biol. Chem.*, *266*: 13621-13626, 1991.
51. Hamasaki, Y., Kitzler, J., Hardman, R., Nettesheim, P., and Eling, T. E. Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. *Arch. Biochem. Biophys.*, *304*: 226-234, 1993.
52. Nanayama, T., Hara, S., Inoue, H., Yokoyama, C., and Tanabe, T. Regulation of two isozymes of prostaglandin endoperoxide synthase and thromboxane synthase in human monoblastoid cell line U937. *Prostaglandins*, *49*: 371-382, 1995.
53. Murakami, M., Matsumoto, R., Urade, Y., Austen, K. F., and Arm, J. P. c-kit ligand mediates increased expression of cytosolic phospholipase A<sub>2</sub>, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D<sub>2</sub> synthase and increased IgE-dependent prostaglandin D<sub>2</sub> generation in immature mouse mast cells. *J. Biol. Chem.*, *270*: 3239-3246, 1995.
54. Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueryet, J.-P., Ford-Hutchinson, A. W., Gordon, R., Greig, G., Gresser, M., Guay, J., Kargmann, S., Leger, S., Mancini, J. A., O'Neill, G., Ouellet, M., Rodger, I. W., Therien, M., Wang, Z., Webb, J. K., Wong, E., Xu, L., Young, R. N., Zamboni, R., Prasit, P., and Chan, C.-C. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. *Br. J. Pharmacol.*, *121*: 105-117, 1997.
55. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology*, *107*: 1183-1188, 1994.
56. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. *Cancer Res.*, *55*: 3785-3789, 1995.
57. Kutcher, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., White, R. L., and Prescott, S. M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. *Proc. Natl. Acad. Sci. USA*, *93*: 4816-4820, 1996.
58. DuBois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. *Gastroenterology*, *110*: 1259-1262, 1996.
59. Smalley, W. E., and DuBois, R. N. Colorectal cancer and non steroidal anti-inflammatory drugs. *Adv. Pharmacol.*, *39*: 1-20, 1997.
60. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hyland, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N. Engl. J. Med.*, *328*: 1313-1316, 1993.
61. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. *Cancer Res.*, *56*: 4566-4569, 1996.
62. Yoshimi, N., Kawabata, K., Hara, A., Matsunaga, K., Yamada, Y., and Mori, H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. *Jpn. J. Cancer Res.*, *88*: 1044-1051, 1997.
63. Nakatsugi, S., Fukutake, M., Takahashi, M., Fukuda, K., Isoi, T., Taniguchi, Y., Sugimura, T., and Wakabayashi, K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. *Jpn. J. Cancer Res.*, *88*: 1117-1120, 1997.
64. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. *Cancer Res.*, *58*: 409-412, 1998.
65. Liu, X.-H., and Rose, D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. *Cancer Res.*, *56*: 5125-5127, 1996.
66. Parrett, M. L., Harris, R. E., Joarder, F. S., Ross, M. S., Clausen, K. P., and Robertson, F. M. Cyclooxygenase-2 gene expression in human breast cancer. *Int. J. Oncol.*, *10*: 503-507, 1997.
67. Huang, M., Stolina, M., Sharma, S., Mao, J. T., Zhu, L., Miller, P. W., Wollman, J., Herschman, H., and Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res.*, *58*: 1208-1216, 1998.
68. Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahan, G., Brown, M., and Lazar, M. A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J. Biol. Chem.*, *270*: 23975-23983, 1995.
69. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell*, *83*: 493-501, 1995.
70. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell*, *93*: 705-716, 1998.
71. Bradley, R. S., and Brown, A. M. C. The proto-oncogene *int-1* encodes a secreted protein associated with the extracellular matrix. *EMBO J.*, *9*: 1569-1575, 1990.